| # | Title | Journal | Year | Citations |
|---|
| 1 | Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables | Lancet Diabetes and Endocrinology,the | 2018 | 1,430 |
| 2 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials | Lancet Diabetes and Endocrinology,the | 2019 | 961 |
| 3 | Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome | Lancet Diabetes and Endocrinology,the | 2014 | 938 |
| 4 | Vitamin D status and ill health: a systematic review | Lancet Diabetes and Endocrinology,the | 2014 | 890 |
| 5 | Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people | Lancet Diabetes and Endocrinology,the | 2015 | 838 |
| 6 | Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases | Lancet Diabetes and Endocrinology,the | 2014 | 760 |
| 7 | Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study | Lancet Diabetes and Endocrinology,the | 2020 | 733 |
| 8 | Preconceptional and maternal obesity: epidemiology and health consequences | Lancet Diabetes and Endocrinology,the | 2016 | 732 |
| 9 | Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study | Lancet Diabetes and Endocrinology,the | 2015 | 719 |
| 10 | Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement | Lancet Diabetes and Endocrinology,the | 2019 | 687 |
| 11 | Practical recommendations for the management of diabetes in patients with COVID-19 | Lancet Diabetes and Endocrinology,the | 2020 | 680 |
| 12 | Diabetes: a 21st century challenge | Lancet Diabetes and Endocrinology,the | 2014 | 679 |
| 13 | Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study | Lancet Diabetes and Endocrinology,the | 2020 | 677 |
| 14 | Influence of maternal obesity on the long-term health of offspring | Lancet Diabetes and Endocrinology,the | 2017 | 668 |
| 15 | COVID-19 in people with diabetes: understanding the reasons for worse outcomes | Lancet Diabetes and Endocrinology,the | 2020 | 668 |
| 16 | Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK | Lancet Diabetes and Endocrinology,the | 2018 | 665 |
| 17 | The obesity transition: stages of the global epidemic | Lancet Diabetes and Endocrinology,the | 2019 | 662 |
| 18 | 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension | Lancet Diabetes and Endocrinology,the | 2017 | 635 |
| 19 | Epidemiology and determinants of obesity in China | Lancet Diabetes and Endocrinology,the | 2021 | 624 |
| 20 | Obesity, inflammation, and the gut microbiota | Lancet Diabetes and Endocrinology,the | 2015 | 617 |
| 21 | Osteoporosis treatment: recent developments and ongoing challenges | Lancet Diabetes and Endocrinology,the | 2017 | 615 |
| 22 | Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data | Lancet Diabetes and Endocrinology,the | 2015 | 604 |
| 23 | Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort | Lancet Diabetes and Endocrinology,the | 2017 | 595 |
| 24 | SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis | Lancet Diabetes and Endocrinology,the | 2019 | 595 |
| 25 | Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications | Lancet Diabetes and Endocrinology,the | 2013 | 594 |
| 26 | Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment | Lancet Diabetes and Endocrinology,the | 2014 | 591 |
| 27 | Exercise management in type 1 diabetes: a consensus statement | Lancet Diabetes and Endocrinology,the | 2017 | 588 |
| 28 | Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis | Lancet Diabetes and Endocrinology,the | 2018 | 582 |
| 29 | Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial | Lancet Diabetes and Endocrinology,the | 2019 | 569 |
| 30 | Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies | Lancet Diabetes and Endocrinology,the | 2019 | 566 |
| 31 | Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study | Lancet Diabetes and Endocrinology,the | 2017 | 564 |
| 32 | Iodine deficiency and thyroid disorders | Lancet Diabetes and Endocrinology,the | 2015 | 556 |
| 33 | Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study | Lancet Diabetes and Endocrinology,the | 2014 | 535 |
| 34 | Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial | Lancet Diabetes and Endocrinology,the | 2015 | 535 |
| 35 | Sweetening of the global diet, particularly beverages: patterns, trends, and policy responses | Lancet Diabetes and Endocrinology,the | 2016 | 524 |
| 36 | The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study | Lancet Diabetes and Endocrinology,the | 2017 | 511 |
| 37 | Type 2 diabetes in adolescents and young adults | Lancet Diabetes and Endocrinology,the | 2018 | 493 |
| 38 | Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial | Lancet Diabetes and Endocrinology,the | 2019 | 482 |
| 39 | The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management | Lancet Diabetes and Endocrinology,the | 2014 | 473 |
| 40 | Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial | Lancet Diabetes and Endocrinology,the | 2016 | 473 |
| 41 | Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial | Lancet Diabetes and Endocrinology,the | 2014 | 470 |
| 42 | Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials | Lancet Diabetes and Endocrinology,the | 2018 | 460 |
| 43 | Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial | Lancet Diabetes and Endocrinology,the | 2017 | 452 |
| 44 | Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis | Lancet Diabetes and Endocrinology,the | 2018 | 451 |
| 45 | Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial | Lancet Diabetes and Endocrinology,the | 2018 | 443 |
| 46 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials | Lancet Diabetes and Endocrinology,the | 2021 | 437 |
| 47 | Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions | Lancet Diabetes and Endocrinology,the | 2014 | 431 |
| 48 | Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study | Lancet Diabetes and Endocrinology,the | 2014 | 431 |
| 49 | The link between depression and diabetes: the search for shared mechanisms | Lancet Diabetes and Endocrinology,the | 2015 | 426 |
| 50 | Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study | Lancet Diabetes and Endocrinology,the | 2018 | 417 |
